View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2013	Nov. 06, 2013
Document Information [Line Items]
Entity Registrant Name	SafeStitch Medical, Inc.
Entity Central Index Key	0000876378
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		168,396,174

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Sales	$ 362	$ 531	$ 1,212	$ 1,741
Operating Expenses
Cost of goods sold	2,059	1,077	4,096	3,465
Research and development	2,909	1,228	7,855	4,552
Sales and marketing	437	1,025	1,490	2,991
General and administrative	1,279	777	2,665	2,176
Merger expenses	2,891	0	2,891	0
Total Operating Expenses	9,575	4,107	18,997	13,184
Operating Loss	(9,213)	(3,576)	(17,785)	(11,443)
Other (Expense) Income
Remeasurement of fair value of preferred stock warrant liability	(1,800)	0	(1,800)	0
Interest expense, net	(252)	(94)	(742)	(251)
Total Other (Expense) Income, net	(2,052)	(94)	(2,542)	(251)
Net Loss	(11,265)	(3,670)	(20,327)	(11,694)
Other comprehensive income (loss)	0	0	0	0
Comprehensive loss	$ (11,265)	$ (3,670)	$ (20,327)	$ (11,694)
Net loss per share - basic and diluted (in dollars per share)	$ (0.21)	$ (0.68)	$ (0.95)	$ (2.17)
Weighted average common shares outstanding - basic and diluted (in shares)	52,921	5,391	21,409	5,391

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 23,829	$ 8,896
Short-term investments	1,104	907
Accounts receivable, net	294	536
Accounts receivable - related party	24	0
Interest receivable	10	16
Inventory, net	766	1,382
Other current assets	1,033	235
Total Current Assets	27,060	11,972
Restricted cash	375	375
Property and equipment, net	1,823	1,767
OTHER ASSETS
Intellectual property, net	2,866	3,241
Trade names	10	0
Goodwill	93,670	0
Other long term assets	129	205
Total Assets	125,933	17,560
Current Liabilities
Accounts payable	2,567	515
Related party payable	0	6
Accrued expenses	1,078	538
Note payable - current portion	3,795	1,519
Total Current Liabilities	7,440	2,578
Long Term Liabilities
Preferred stock warrant liability	0	109
Note payable - less current portion	5,604	8,481
Total Liabilities	13,044	11,168
Commitments and Contingencies
Stockholders' Equity (Deficit)
Common stock	168	5
Additional paid-in capital	172,757	1,288
Accumulated deficit	(90,233)	(69,906)
Total Stockholders' Equity (Deficit)	112,889	(68,613)
Total Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)	125,933	17,560
Series A Redeemable Convertible Preferred Stock [Member]
Long Term Liabilities
Redeemable Convertible Preferred Stock	0	19,885
Series B Redeemable Convertible Preferred Stock [Member]
Long Term Liabilities
Redeemable Convertible Preferred Stock	0	40,016
Series B-1 Redeemable Convertible Preferred Stock [Member]
Long Term Liabilities
Redeemable Convertible Preferred Stock	0	15,104
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred stock	$ 30,197	$ 0

Consolidated Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Stockholders Equity
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	113,000,000
Common stock, shares issued	167,504,447	4,674,495
Common stock, shares outstanding	167,504,447	4,674,495
Series A Redeemable Convertible Preferred Stock [Member]
Stockholders Equity
Redeemable convertible preferred stock, par value (in dollars per share)		$ 0.001
Redeemable convertible preferred stock, shares authorized		5,734,402
Redeemable convertible preferred stock, shares issued		5,696,261
Redeemable convertible preferred stock, shares outstanding		5,696,261
Series B Redeemable Convertible Preferred Stock [Member]
Stockholders Equity
Redeemable convertible preferred stock, par value (in dollars per share)		$ 0.001
Redeemable convertible preferred stock, shares authorized		11,504,298
Redeemable convertible preferred stock, shares issued		11,489,972
Redeemable convertible preferred stock, shares outstanding		11,489,972
Series B-1 Redeemable Convertible Preferred Stock [Member]
Stockholders Equity
Redeemable convertible preferred stock, par value (in dollars per share)		$ 0.001
Redeemable convertible preferred stock, shares authorized		48,454,545
Redeemable convertible preferred stock, shares issued		45,998,220
Redeemable convertible preferred stock, shares outstanding		45,998,220
Series B Convertible Preferred Stock [Member]
Stockholders Equity
Preferred stock, par value (in dollars per share)	$ 0.01
Preferred stock, shares authorized	25,000,000
Preferred stock, shares issued	7,569,704.4
Preferred stock, shares outstanding	7,569,704.4

Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) - 9 months ended Sep. 30, 2013 - USD ($) shares in Thousands, $ in Thousands	Total	Series A Preferred Stock	Series B Preferred Stock	Series B-1 Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	$ (68,613)	$ 19,885	$ 40,016	$ 15,104	$ 5	$ 1,288	$ (69,906)
Beginning Balance, Shares at Dec. 31, 2012		5,696	11,490	45,998	4,675
Accretion of issuance costs	(40)	$ 0	$ 31	$ 9	$ 0	(40)	0
Stock-based compensation	484	0	0	0	0	484	0
Exercise of stock options	34	$ 0	$ 0	$ 0	$ 0	34
Exercise of stock options, Shares		0	0	0	53
Exercise of warrants	50	$ 0	$ 0	$ 0	$ 0	50	0
Exercise of warrants, Shares		0	0	0	150
Reverse acquisition recapitalization adjustment	169,195	$ (19,885)	$ (40,047)	$ (15,113)	$ 163	169,032
Reverse acquisition recapitalization adjustment, Shares		(5,696)	(11,490)	(45,998)	162,895
Redemption of TransEnterix shares for cash to non-accredited investors					$ 0
Redemption of TransEnterix shares for cash to non-accredited investors, Shares					271
Conversion of preferred stock warrants to common stock warrants	1,909					1,909
Issuance of Preferred Stock	30,197		$ 30,197
Issuance of Preferred Stock, Shares			7,570
Net loss	(20,327)						(20,327)
Ending Balance at Sep. 30, 2013	$ 112,889	$ 0	$ 30,197	$ 0	$ 168	$ 172,757	$ (90,233)
Ending Balance, Share at Sep. 30, 2013		0	7,570	0	167,502

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating Activities
Net loss	$ (20,327)	$ (11,694)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	1,064	1,444
Amortization of debt issuance costs	78	23
Remeasurement of fair value of preferred stock warrant liability	1,800	0
Accretion/amortization of bond discount/premium	(1)	1
Stock-based compensation	484	274
Gain on disposal of property and equipment	32	4
Impairment loss on property and equipment	304	0
Changes in operating assets and liabilities:
Accounts receivable	251	(232)
Interest receivable	6	(62)
Inventory	667	(282)
Other current and long term assets	(527)	(122)
Accounts payable	1,444	(351)
Related party payable	173	(10)
Accrued expenses	505	125
Net cash and cash equivalents used in operating activities	(14,047)	(10,901)
Investing Activities
Purchase of investments	(1,104)	(4,702)
Proceeds from sale and maturities of investments	907	0
Cash received in acquisition of a business, net of cash paid	305	0
Purchase of property and equipment	(724)	(92)
Proceeds from sale of property and equipment	0	49
Net cash and cash equivalents used in investing activities	(616)	(4,745)
Financing Activities
Proceeds from issuance of debt	1,998	4,000
Payment of debt	(601)	0
Proceeds from issuance of preferred stock, net of issuance costs	28,199	268
Proceeds from exercise of stock options	0	3
Net cash and cash equivalents provided by financing activities	29,596	4,271
Net increase (decrease) in cash and cash equivalents	14,933	(11,375)
Cash and Cash Equivalents, beginning of period	8,896	14,004
Cash and Cash Equivalents, end of period	23,829	2,629
Supplemental Disclosure for Cash Flow Information
Interest paid	625	219
Supplemental Schedule of Noncash Investing and Financing Activities
Issuance of preferred stock warrants and debt issuance costs	128	63
Conversion of bridge notes to preferred stock	1,998	0
Conversion of preferred stock warrants to common stock warrants	$ 1,909	$ 0

Description of Business

9 Months Ended

Sep. 30, 2013

Business Combination, Description [Abstract]

Description of Business

1.	Description of Business

SafeStitch Medical, Inc., a Delaware corporation (“SafeStitch”), was originally incorporated in August 1988 as NCS Ventures Corp., after which SafeStitch’s name was changed to Cellular Technical Services Company, Inc. (“Cellular Technical”). On September 4, 2007, SafeStitch acquired SafeStitch LLC, and, in January 2008, Cellular Technical changed its name to SafeStitch Medical, Inc. On September 3, 2013, SafeStitch consummated a merger with TransEnterix, Inc. (“TransEnterix”) in which a wholly owned subsidiary of the Company merged with TransEnterix, with TransEnterix being the surviving entity (the “Merger”). As such, the term the “Company” refers to the combined enterprise of SafeStitch Medical, Inc. and TransEnterix, the term “SafeStitch” refers to the business of SafeStitch Medical, Inc. prior to the Merger and the term “TransEnterix” refers to the business of TransEnterix, Inc., prior to the Merger. See Note 14 for a description of the Merger and the related transactions. The Merger is being treated as a reverse acquisition for financial accounting and reporting purposes, with SafeStitch as the acquired entity and TransEnterix as the acquirer. As a result, the assets and liabilities and the historical operations that are reflected in the Company’s financial statements filed with the SEC are those of TransEnterix, and the Company’s assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of TransEnterix and SafeStitch effective September 3, 2013. Effective September 3, 2013, the Company is headquartered in Morrisville, North Carolina.

The Company is a medical device company that is focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot™ System (“SurgiBot”). The SurgiBot utilizes flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, at the patient’s bedside. The flexible nature of the SurgiBot allows for multiple instruments to be introduced and deployed through a single space, thereby offering room for visualization and manipulation once in the body. The SurgiBot also integrates three-dimensional, or 3-D, high definition vision technology. The Company has also commercialized the SPIDER® Surgical System, (the “SPIDER System”) a manual laparoscopic system in the United States, Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels controlled directly by the surgeon, allowing for multiple instruments to be introduced via a single small incision. The product is U.S. Food and Drug Administration cleared and has received CE Mark approval. The Company sells its products through a direct sales force and international distributors.

Prior to the Merger, SafeStitch was focused on developing its Gastroplasty Device for the treatment of obesity and GERD, and has developed surgical devices, including the SMART Dilator™ and Bite Blocks, to be utilized in treating obesity, GERD, esophageal strictures and airway problems during endoscopy. SafeStitch also has a 510k cleared and CE Mark approved stapler called the AMID Hernia Fixation Device.

The Company operates in one business segment.

Concurrent with the closing of the Merger on September 3, 2013, the Company completed a private placement of 7,544,704.4 shares of its Series B Convertible Preferred Stock (“Preferred Stock”), par value $0.01, each share of which is convertible, subject to certain conditions, into ten (10) shares of common stock, par value $0.001 per share (“Common Stock”) for a purchase price of $4.00 per share of Preferred Stock, which was paid in cash, cancellation of certain indebtedness of TransEnterix or a combination thereof. The Company issued and sold an additional 25,000 shares of Preferred Stock within the period provided in the Securities Purchase Agreement.

The Company is subject to a number of risks similar to other similarly-sized companies in the medical device industry. These risks include, without limitation, the historical lack of profitability, our ability to raise additional capital, our ability to successfully develop, clinically test and commercialize our products, the timing and outcome of the regulatory review process for our products, changes in the health care and regulatory environments of the United States and other countries in which we intend to operate, our ability to attract and retain key management, marketing and scientific personnel, competition from new entrants, our ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights, our ability to successfully transition from a research and development company to a marketing, sales and distribution concern, and our ability to identify and pursue development of additional products.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of presentation

The Company has prepared the accompanying unaudited consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. The consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's Form 8-K filed with the Securities and Exchange Commission Securities Act of 1933 filed September 6, 2013. The accompanying unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company’s management, necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The principal estimates relate to accounts receivable reserves, inventory valuation, stock-based compensation, accrued expenses, income tax valuation and purchase price accounting related to the acquisition of SafeStitch. Actual results could differ from those estimates. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred operating losses and negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. If the Company is unable to obtain the necessary capital, it will need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

For a description of our critical accounting policies and estimates, please refer to the “Critical Accounting Policies and Estimates” section of the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section contained in our Form 8-K filed with the Securities and Exchange Commission Securities Act of 1933 filed September 6, 2013 and the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. There have been no material changes in any of our accounting policies since December 31, 2012, however the Company has adopted the following new accounting policies related to the Merger.

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain intangible assets are amortized over 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Indefinite-lived intangible assets, such as goodwill are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test.

Debt Issuance Costs

The Company capitalizes costs associated with the issuance of debt instruments and amortizes these costs to interest expense over the term of the related debt agreement using the effective yield amortization method. Unamortized debt issuance costs will be charged to operations when indebtedness under the related credit facility is repaid prior to maturity.

Business Acquisitions

Business acquisitions are accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, “Business Combinations.” ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, “Fair Value Measurements,” as of the acquisition date. For certain assets and liabilities, book value approximates fair value. In addition, ASC 805 establishes that consideration transferred be measured at the closing date of the acquisition at the then-current market price, which may be different than the amount of consideration assumed in the pro forma financial statements. Under ASC 805, acquisition related costs (i.e., advisory, legal, valuation and other professional fees) and certain acquisition-related restructuring charges impacting the target company are expensed in the period in which the costs are incurred. The application of the acquisition method of accounting requires the Company to make estimates and assumptions related to the estimated fair values of net assets acquired. Significant judgments are used during this process, particularly with respect to intangible assets. Generally, intangible assets are amortized over their estimated useful lives. Goodwill and other indefinite-lived intangibles are not amortized, but are annually assessed for impairment. Therefore, the purchase price allocation to intangible assets and goodwill has a significant impact on future operating results.

Impact of Recently Issued Accounting Standards

New accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies that the Company adopts according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s result of operations, financial position or cash flow.

Income Taxes

9 Months Ended

Sep. 30, 2013

Income Taxes [Abstract]

Income Taxes

3.	Income Taxes

Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. The Company computes its interim provision for income taxes by applying the estimated annual effective tax rate method. The Company estimates an annual effective tax rate of 0% for the year ended December 31, 2013 as the Company incurred losses for the nine month period ended September 30, 2013 and is forecasting additional losses through the 4th quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ended December 31, 2013. Due to the Company’s history of losses, there is not sufficient evidence at this time to support the conclusion that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the net deferred tax assets have been reduced by a full valuation allowance. Therefore, no federal or state income taxes are expected and none have been recorded at this time.

The Company’s effective tax rate for each of the nine month periods ended September 30, 2013 and 2012 was 0%. At September 30, 2013, the Company had no unrecognized tax benefits that would affect the Company’s effective tax rate.

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2013

Basic and Diluted Net Loss Per Share [Abstract]

Net Loss Per Common Share

4.	Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss available to common stockholders per common share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. The Company’s potential dilutive common shares, which consist of shares issuable upon the exercise of stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Cash and Cash Equivalents

9 Months Ended

Sep. 30, 2013

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents

5.	Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include money market funds. Cash equivalents are carried at fair market value. At September 30, 2013, the Company had $375,000 of restricted cash in a certificate of deposit securing a line of credit. Related unrealized gains and losses were not material as of September 30, 2013 and December 31, 2012. There have been no unrealized gains or losses reclassified to accumulated other comprehensive income.

Cash and cash equivalents and restricted cash consist of the following:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Cash	$	1,181	$	729
Money market	$	22,648	$	8,167
Total cash and cash equivalents	$	23,829	$	8,896

Restricted cash	$	375	$	375
Total	$	24,204	$	9,271

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

Fair Value

9 Months Ended

Sep. 30, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]

Fair Value

6.	Fair Value

The Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets include available for sale securities classified as cash equivalents and preferred stock warrant liability. ASC 820-10 requires the valuation using a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and therefore, are based primarily upon estimates, are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures.

As prescribed by U.S. GAAP, the Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy.

The determination of where an asset or liability falls in the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures and based on various factors, it is possible that an asset or liability may be classified differently from period to period. However, the Company expects changes in classifications between levels will be rare.

The following are the major categories of assets and liabilities measured at fair value on a recurring basis as of December 31, 2012, and September 30, 2013 (unaudited), using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

	December 31, 2012
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Total
	(Level 1)		(Level 2)		(Level 3)		December 31, 2012

Assets measured at fair value
Cash and Cash Equivalents	$	8,896	$	-	$	-	$	8,896
Restricted Cash		375		-		-		375
Short term investments				907				907

Total Assets measured at fair value	$	9,271	$	907	$	-	$	10,178

Liabilities measured at fair value
Preferred Stock Warrant Liability	$	-	$	-	$	(109)	$	(109)

Total Liabilities measured at fair value	$	-	$	-	$	(109)	$	(109)

	September 30, 2013 (unaudited)
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Total
	(Level 1)		(Level 2)		(Level 3)		September 30, 2013
Assets measured at fair value
Cash and Cash Equivalents	$	23,829	$	-	$	-	$	23,829
Restricted Cash		375		-		-		375
Short term investments		-	$	1,104			$	1,104

Total Assets measured at fair value	$	24,204	$	1,104	$	-	$	25,308

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

9 Months Ended

Sep. 30, 2013

Investments, Debt and Equity Securities [Abstract]

Investments

7.	Investments

Investments consist of short-term corporate bonds carried at amortized cost using the effective interest method. The Company classifies its corporate bonds as held-to-maturity based upon management’s positive intention and ability to hold these securities until their maturity dates. The aggregate fair values of investment securities along with unrealized gains and losses determined on an individual investment security basis are as follows:

	(In thousands)
	Amortized Cost		Unrealized Gain		Unrealized (Loss)		Fair Value
September 30, 2013
Corporate bonds	$	1,105	$	-	$	(1)	$	1,104

December 31,2012
Corporate bonds	$	907	$	-	$	-	$	907

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Accounts Receivable, Net

9 Months Ended

Sep. 30, 2013

Receivables [Abstract]

Accounts Receivable, Net

8.	Accounts Receivable, Net

The following table presents the components of accounts receivable:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Gross accounts receivable	$	326	$	586
Allowance for uncollectible accounts		(32)		(50)
Total accounts receivable, net	$	294	$	536

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2013

Inventory Disclosure [Abstract]

Inventories

9.	Inventories

The following table presents the components of inventories:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Finished goods	$	701	$	708
Raw materials		691		784
Work in process		173		-
Reserve for excess and obsolete inventory		(799)		(110)
Total inventories	$	766	$	1,382

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

10.

Goodwill and Intangible Assets

The following table presents the carrying value of the components of goodwill and intangible assets at the balance sheet dates:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Goodwill	$	93,670	$	-

Intangible assets:
Intellectual property	$	5,000	$	5,000
Tradenames		10		-
Amortization of intangible assets		(2,134)		(1,759)
Total intangible assets	$	2,876	$	3,241

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

Accrued Expenses

11.

Accrued Expenses

The following table presents the components of accrued expenses:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Vacation	$	230	$	66
Bonus		315		-
Vendors		146		76
Legal and professional fees		70		53
Interest		69		43
Corporate credit card		65		47
Salaries and commissions		52		41
Rent		50		82
Consulting		-		67
Other		81		63
Total accrued expenses	$	1,078	$	538

Debt

9 Months Ended

Sep. 30, 2013

Debt [Abstract]

Debt

12.

Debt

In connection with the Merger, the Company assumed and became the borrower under TransEnterix’ s outstanding credit facility pursuant to the terms of the Loan and Security Agreement, dated as of January 17, 2012, (the “Loan Agreement”) , among TransEnterix, Silicon Valley Bank, as collateral agent (the “Collateral Agent”), and Silicon Valley Bank and Oxford Finance, LLC, as lenders (the “Lenders”). The Second Amendment to Loan Agreement, dated as of September 3, 2013, amends the Loan and Security Agreement among the Collateral Agent, the lenders party thereto, and SafeStitch (as so amended, the “Amended Loan Agreement”). The Amended Loan Agreement evidences a term loan, which will mature on January 1, 2016 (the “Term Loan”). The following table presents the components of long-term debt:

	September 30,
	2013
	(In thousands)
	(unaudited)

Total long-term debt		9,399
Less: Current portion of long-term debt		3,795
Total long-term debt, net of current portion	$	5,604

The Term Loan bears interest at a fixed rate equal to 8.75%.

Commencing August 2013, the Amended Loan Agreement provides for the amortization of principal (in the form of level monthly payments of principal and interest). The Term Loan will be required to be prepaid if the Term Loan is accelerated following an event of default. In addition, the Company is permitted to prepay the Term Loan in full at any time upon 10 days’ written notice to the Lenders. Upon the earliest to occur of the maturity date, acceleration of the Term Loan, or prepayment of the Term Loan, the Company is required to make a final payment equal to the original principal amount of the Term Loan multiplied by 3.33% (the “Final Payment Fee”). Any prepayment, whether mandatory or voluntary, must include the Final Payment Fee, interest at the default rate (which is the rate otherwise applicable plus 5%) with respect to any amounts past due, the Collateral Agent’s and the Lenders’ expenses, and all other obligations that are due and payable to the Collateral Agent and the Lenders.

The Amended Loan Agreement is secured by a security interest in substantially all assets of the Company and any future subsidiaries, other than intellectual property. The Amended Loan Agreement contains customary representations (tested on a continual basis) that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; fail to appoint a chief executive officer, chief financial officer, and chief technology officer upon vacancy; undergo a change in control; add or change business locations; and engage in businesses that are not related to the Company’s existing business.

Warrants

9 Months Ended

Sep. 30, 2013

Warrants [Abstract]

Warrants

13.

Warrants

On March 22, 2013, SafeStitch entered into a stock purchase agreement (the “2013 Stock Purchase Agreement”) with approximately 17 investors (the "2013 PIPE Investors") pursuant to which the 2013 PIPE Investors agreed to purchase an aggregate of approximately 12,100,000 shares of common stock at a price of $0.25 per share for aggregate consideration of approximately $3.0 million. Included in this private placement was the issuance of PIPE Warrants to purchase approximately 6,050,000 common shares, representing one warrant for every two common shares purchased, with an exercise price of $0.33 per share and five year expiration. Among the Investors purchasing Shares were related parties who purchased 6.4 million shares and received 3.2 million warrants. During the three months ended September 30, 2013, 200,000 warrants were exercised.

On January 17, 2012, TransEnterix entered into the SVB-Oxford Loan and Security Agreement with Silicon Valley Bank (“SVB”) and Oxford Finance LLC (“Oxford”). Pursuant to this agreement, TransEnterix issued warrants to SVB and Oxford on January 17, 2012 and December 21, 2012, respectively, to purchase shares of capital stock. Following the Merger, these warrants were assumed by the Company and are now exercisable for an aggregate of approximately 1,397,937 shares of Common Stock.

Closing of Merger and Financing Transaction

9 Months Ended

Sep. 30, 2013

Merger and Financial disclosure [Abstract]

Closing of Merger and Financing Transaction

14.

Closing of Merger and Financing Transaction

On September 3, 2013, the Company consummated the Merger in which a wholly owned subsidiary of the Company merged with TransEnterix, pursuant to the Merger Agreement. Under the terms of the Merger Agreement, TransEnterix remained as the surviving corporation and as a wholly-owned subsidiary of the Company.

Upon the closing of the Merger, and in accordance with the terms of the Merger Agreement, the Company issued an aggregate of 105,549,746 shares of the Company’s common stock as Merger consideration and paid $293,000 to unaccredited investors in lieu of common stock.

During July 2013, TransEnterix issued promissory notes (the “Bridge Notes”) in the aggregate principal amount of $2.0 million, as contemplated by the Merger Agreement. The Bridge Notes bore interest at a rate of 8% per annum. The Bridge Notes were not secured by any collateral and were subordinated in right of payment to the loan evidenced by the Loan and Security Agreement dated as of January 17, 2012, among Oxford , SVB and TransEnterix. The Bridge Notes were converted into Series B preferred stock at the effective time of the Merger.

Concurrent with the closing of the Merger, and in accordance with the terms of a Securities Purchase Agreement, the Company issued 7,544,704.4 shares of Preferred Stock, each share of which is convertible, subject to certain conditions, into ten (10) shares of Common Stock, for a purchase price of $4.00 per share of Preferred Stock, which was paid in cash, cancellation of certain Bridge Notes of TransEnterix or a combination thereof. Pursuant to the Securities Purchase Agreement, the Company issued and sold an additional 25,000 shares of Preferred Stock within the period provided in the Securities Purchase Agreement resulting in gross proceeds to the Company of approximately $100,000.

At the closing of the Merger, each outstanding share of capital stock of TransEnterix was cancelled and extinguished and converted into the right to receive a portion of the Merger consideration in accordance with the Merger Agreement. The Bridge Notes were terminated at closing of the Merger, and the holders of such Bridge Notes received Merger consideration in accordance with the Merger Agreement. All stock option plans of TransEnterix, each outstanding option to purchase common stock of TransEnterix, whether vested or unvested, and each warrant to acquire capital stock of TransEnterix were assumed by the Company concurrent with the closing of the Merger.

The Merger effectuated on September 3, 2013 qualified as a tax-free reorganization under Section 368 of the Internal Revenue Code. As a result of the Merger, the utilization of certain tax attributes of the Company may be limited in future periods under the rules prescribed under Section 382 of the Internal Revenue Code.

The Company’s assets and liabilities are presented at their preliminary estimated fair values, with the excess of the purchase price over the sum of these fair values presented as goodwill. The Company has not completed the detailed valuation studies necessary to arrive at the required estimates of fair market value of its assets and liabilities and the related allocations of purchase price. The valuations of assets and liabilities are in process and are not expected to be finalized until later in 2013, as information may become available within the measurement period which indicates a potential change to these valuations. Accordingly, the final allocations of and the effects on the results of operations may differ materially from the preliminary allocations amounts included herein.

The following table summarizes the purchase price:

Common shares outstanding at the date of merger (in thousands)		61,749
Closing price per share	$	1.52
	$	93,858
Cash consideration		293
Total purchase price	$	94,151

The purchase price was allocated to the net assets acquired utilizing the methodology prescribed in ASC 805. The Company recorded goodwill of $93.7 million after recording net assets acquired at fair value as presented in the following table.

The following table summarizes the allocation of the purchase price to the net assets acquired (in thousands):

Cash and cash equivalents	$	597
Accounts receivable		9
Accounts receivable, related party		45
Inventory		50
Other current assets		53
Property and equipment		357
Other long-term asset		2
Intangible assets		10
Goodwill		93,670
Total assets acquired	$	94,793
Accounts payable and other liabilities		642
Total purchase price	$	94,151

Following the announcement of the Merger, the SafeStitch stock price increased prior to the Merger closing date of September 3, 2013, generating additional goodwill. As a result, there may be impairment in the future and the impairment of goodwill will be assessed annually.

The Company allocated $10,000 of the purchase price to identifiable intangible assets of tradenames that met the separability and contractual legal criterion of ASC 805. The tradename will be amortized using the straight-line method over 10 years.

The results of operations of SafeStitch have been included in our consolidated financial statements from the date of the acquisition. The following pro forma results of operations assume the acquisition of SafeStitch as of the beginning of 2012. The pro forma results for the nine months ended September 30, 2013 presented below reflect our historical data and the historical data of the SafeStitch business. The pro forma results of operations presented below may not be indicative of the results the Company would have achieved had the Company completed the acquisition on January 1, 2013, or that the Company may achieve in the future.

					Historical
	SafeStitch Medical, Inc.				Results of		Pro Forma		Pro Forma
	(the Company)		SafeStitch		SafeStitch Medical, Inc		Adjustments		Results
	(in thousands)

Revenue	$	1,212	$	25	$	1,237	$	-	$	1,237
Net loss	$	(20,327)	$	(2,062)	$	(22,389)	$	-	$	(22,389)

Historical TransEnterix loss per common share - basic and diluted					$	(0.13)
Pro forma loss per common share - basic and diluted:					$	(0.13)
Pro forma loss					$	(22,389)
Pro forma weighted average common shares						167,502
Pro forma loss per common share					$	(0.13)

Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

15.

Subsequent Events

On October 24, 2013, the Company entered into a new warehouse operating lease for a period of 52 months commencing in January 2014, with an option to renew for an additional six years. The future minimum lease payments for this operating lease are as follows:

Year ending December 31,
2014	$	83
2015		114
2016		117
2017		121
2018		124
	$	559

On or about October 29, 2013, the Company received written consents in lieu of a meeting of stockholders from holders of approximately 89% of our common stock and approximately 98% of our Preferred Stock representing a majority of the total issued and outstanding shares of capital voting stock of the Company to authorize the Board to approve the following:

(1) to file an Amended and Restated Certificate of Incorporation (the “Restated Certificate) which (a) increases the number of authorized shares of Common Stock from 225,000,000 to 750,000,000 shares, and (b) makes certain other changes;

(2) to file the Restated Certificate to change the name of the Company to “TransEnterix, Inc.” (the “Name Change”);

(3) to approve the amendment and restatement of our 2007 Incentive Compensation Plan (“2007 Plan”) (a) increasing the number of shares of common stock authorized for issuance under the 2007 Plan from 5,000,000 shares of Common Stock to 24,700,000 shares of common stock, (b) increasing the per-person award limitations for Options or Stock Appreciation Rights from 1,000,000 to 2,500,000 shares and for Restricted Stock, Deferred Stock, Performance Shares and/or Other Stock-Based Awards from 500,000 to 1,000,000 shares, and (c) changing the name of the 2007 Plan to reflect the Name Change; and

(4) to approve an amendment and restatement of our Bylaws, changing the name of our Bylaws to reflect the Name Change.

The Company expects the matters approved by a majority of its common stockholders and Series B preferred stockholders to be effective by December 31, 2013. Following the effectiveness of the Restated Certificate as filed with the State of Delaware, each of the Series B Preferred Shares issued in September 2013 will automatically convert into 10 shares of common stock as set forth in the Certificate of Designation of the Series B Convertible Preferred Stock.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Summary Of Significant Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

Identifiable Intangible Assets and Goodwill

Identifiable Intangible Assets and Goodwill

Debt Issuance Costs

Debt Issuance Costs

Business Acquisitions

Business Acquisitions

Impact of Recently Issued Accounting Standards

Impact of Recently Issued Accounting Standards

Cash and Cash Equivalents (Tables)

9 Months Ended

Sep. 30, 2013

Cash and Cash Equivalents [Abstract]

Summary of Cash and Cash Equivalents

Cash and cash equivalents and restricted cash consist of the following:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Cash	$	1,181	$	729
Money market	$	22,648	$	8,167
Total cash and cash equivalents	$	23,829	$	8,896

Restricted cash	$	375	$	375
Total	$	24,204	$	9,271

Fair Value (Tables)

9 Months Ended

Sep. 30, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]

Summary of Fair Value

	December 31, 2012
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Total
	(Level 1)		(Level 2)		(Level 3)		December 31, 2012

Assets measured at fair value
Cash and Cash Equivalents	$	8,896	$	-	$	-	$	8,896
Restricted Cash		375		-		-		375
Short term investments		-		907		-		907

Total Assets measured at fair value	$	9,271	$	907	$	-	$	10,178

Liabilities measured at fair value
Preferred Stock Warrant Liability	$	-	$	-	$	(109)	$	(109)

Total Liabilities measured at fair value	$	-	$	-	$	(109)	$	(109)

	September 30, 2013 (unaudited)
	(In thousands)
Description	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs		Total
	(Level 1)		(Level 2)		(Level 3)		September 30, 2013
Assets measured at fair value
Cash and Cash Equivalents	$	23,829	$	-	$	-	$	23,829
Restricted Cash		375		-		-		375
Short term investments		-	$	1,104		-	$	1,104

Total Assets measured at fair value	$	24,204	$	1,104	$	-	$	25,308

Investments (Tables)

9 Months Ended

Sep. 30, 2013

Investments, Debt and Equity Securities [Abstract]

Summary of Investment security

The aggregate fair values of investment securities along with unrealized gains and losses determined on an individual investment security basis are as follows:

	(In thousands)
	Amortized Cost		Unrealized Gain		Unrealized (Loss)		Fair Value
September 30, 2013
Corporate bonds	$	1,105	$	-	$	(1)	$	1,104

December 31,2012
Corporate bonds	$	907	$	-	$	-	$	907

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Accounts Receivable, Net (Tables)

9 Months Ended

Sep. 30, 2013

Receivables [Abstract]

Summary of Accounts receivable

The following table presents the components of accounts receivable:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Gross accounts receivable	$	326	$	586
Allowance for uncollectible accounts		(32)		(50)
Total accounts receivable, net	$	294	$	536

Inventories (Tables)

9 Months Ended

Sep. 30, 2013

Inventory Disclosure [Abstract]

Summary of Inventories

The following table presents the components of inventories:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Finished goods	$	701	$	708
Raw materials		691		784
Work in process		173		-
Reserve for excess and obsolete inventory		(799)		(110)
Total inventories	$	766	$	1,382

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets and Goodwill

The following table presents the carrying value of the components of goodwill and intangible assets at the balance sheet dates:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Goodwill	$	93,670	$	-

Intangible assets:
Intellectual property	$	5,000	$	5,000
Tradenames		10		-
Amortization of intangible assets		(2,134)		(1,759)
Total intangible assets	$	2,876	$	3,241

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

Summary of Accrued Expenses

The following table presents the components of accrued expenses:

	September 30,		December 31,
	2013		2012
	(In thousands)
	(unaudited)
Vacation	$	230	$	66
Bonus		315		-
Vendors		146		76
Legal and professional fees		70		53
Interest		69		43
Corporate credit card		65		47
Salaries and commissions		52		41
Rent		50		82
Consulting		-		67
Other		81		63
Total accrued expenses	$	1,078	$	538

Debt (Tables)

9 Months Ended

Sep. 30, 2013

Debt [Abstract]

Summary of Debt

The following table presents the components of long-term debt:

	September 30,
	2013
	(In thousands)
	(unaudited)

Total long-term debt		9,399
Less: Current portion of long-term debt		3,795
Total long-term debt, net of current portion	$	5,604

Closing of Merger and Financing Transaction (Tables)

9 Months Ended

Sep. 30, 2013

Merger and Financial disclosure [Abstract]

Summary Of Purchase Price

The following table summarizes the purchase price:

Common shares outstanding at the date of merger (in thousands)		61,749
Closing price per share	$	1.52
	$	93,858
Cash consideration		293
Total purchase price	$	94,151

Summary of Business Acquisitions, by Acquisition

The following table summarizes the allocation of the purchase price to the net assets acquired (in thousands):

Cash and cash equivalents	$	597
Accounts receivable		9
Accounts receivable, related party		45
Inventory		50
Other current assets		53
Property and equipment		357
Other long-term asset		2
Intangible assets		10
Goodwill		93,670
Total assets acquired	$	94,793
Accounts payable and other liabilities		642
Total purchase price	$	94,151

Summary of Business Acquisition, Pro Forma Information

The pro forma results of operations presented below may not be indicative of the results the Company would have achieved had the Company completed the acquisition on January 1, 2013, or that the Company may achieve in the future.

					Historical
	SafeStitch Medical, Inc.				Results of		Pro Forma		Pro Forma
	(the Company)		SafeStitch		SafeStitch Medical, Inc		Adjustments		Results
	(in thousands)

Revenue	$	1,212	$	25	$	1,237	$	-	$	1,237
Net loss	$	(20,327)	$	(2,062)	$	(22,389)	$	-	$	(22,389)

Historical TransEnterix loss per common share - basic and diluted					$	(0.13)
Pro forma loss per common share - basic and diluted:					$	(0.13)
Pro forma loss					$	(22,389)
Pro forma weighted average common shares						167,502
Pro forma loss per common share					$	(0.13)

Subsequent Events (Tables)

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Operating Leases of Lessee Disclosure

The future minimum lease payments for this operating lease are as follows:

Year ending December 31,
2014	$	83
2015		114
2016		117
2017		121
2018		124
	$	559

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

Description of Business (Details Textual) - $ / shares	9 Months Ended
Description of Business (Details Textual) - $ / shares	Sep. 30, 2013	Dec. 31, 2012
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion	10
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	7,545
Common Stock, Par or Stated Value Per Share	$ 0.001
Preferred Stock, Par or Stated Value Per Share	$ 0.01
Private Placement [Member] \| Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion	10
Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	25,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01
Series B Convertible Preferred Stock [Member] \| Private Placement [Member]
Share Price	$ 4.00

Summary of Significant Accounting Policies (Details Textual)	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies (Textual) [Abstract]
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years

Income Taxes (Details Textual)	9 Months Ended
Income Taxes (Details Textual)	Sep. 30, 2013	Sep. 30, 2012
Income Taxes (Textual) [Abstract]
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash	$ 1,181	$ 729
Money market	22,648	8,167
Total cash and cash equivalents	23,829	8,896	$ 2,629	$ 14,004
Restricted cash	375	375
Total	$ 24,204	$ 9,271

Cash and Cash Equivalents (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]
Restricted Cash and Cash Equivalents, Current	$ 375	$ 375

Fair value (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Assets measured at fair value
Cash and Cash Equivalents	$ 24,204	$ 9,271
Restricted Cash	375	375
Short term investments	1,104	907
Total Assets measured at fair value	25,308	10,178
Liabilities measured at fair value
Preferred Stock Warrant Liability		(109)
Total Liabilities measured at fair value		(109)
Fair Value, Inputs, Level 1 [Member]
Assets measured at fair value
Cash and Cash Equivalents	23,829	8,896
Restricted Cash	375	375
Short term investments	0
Total Assets measured at fair value	24,204	9,271
Liabilities measured at fair value
Preferred Stock Warrant Liability		0
Total Liabilities measured at fair value		0
Fair Value, Inputs, Level 2 [Member]
Assets measured at fair value
Cash and Cash Equivalents	0	0
Restricted Cash	0	0
Short term investments	1,104	907
Total Assets measured at fair value	1,104	907
Liabilities measured at fair value
Preferred Stock Warrant Liability		0
Total Liabilities measured at fair value		0
Fair Value, Inputs, Level 3 [Member]
Assets measured at fair value
Cash and Cash Equivalents	0	0
Restricted Cash	0	0
Total Assets measured at fair value	$ 0	0
Liabilities measured at fair value
Preferred Stock Warrant Liability		(109)
Total Liabilities measured at fair value		$ (109)

Investments (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Investments [Line Items]
Amortized Cost	$ 1,105	$ 907
Unrealized Gain	0	0
Unrealized (Loss)	(1)	0
Fair Value	$ 1,104	$ 907

Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Accounts Receivable Net [Line Items]
Gross accounts receivable	$ 326	$ 586
Allowance for uncollectible accounts	(32)	(50)
Total accounts receivable, net	$ 294	$ 536

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Inventory [Line Items]
Finished goods	$ 701	$ 708
Raw materials	691	784
Work in process	173	0
Reserve for excess and obsolete inventory	(799)	(110)
Total inventories	$ 766	$ 1,382

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Intangible Assets By Major Class [Line Items]
Goodwill	$ 93,670	$ 0
Intangible assets:
Intellectual property	5,000	5,000
Tradenames	10	0
Amortization of intangible assets	(2,134)	(1,759)
Total intangible assets	$ 2,876	$ 3,241

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Accrued Liabilities [Line Items]
Vacation	$ 230	$ 66
Bonus	315	0
Vendors	146	76
Legal and professional fees	70	53
Interest	69	43
Corporate credit card	65	47
Salaries and commissions	52	41
Rent	50	82
Consulting	0	67
Other	81	63
Total accrued expenses	$ 1,078	$ 538

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Line Of Credit Facility [Line Items]
Total long-term debt	$ 9,399
Less: Current portion of long-term debt	3,795
Total long-term debt, net of current portion	$ 5,604	$ 8,481

Debt (Details Textual)	9 Months Ended
Debt (Details Textual)	Sep. 30, 2013
Line of Credit Facility (Textual) [Abstract]
Final Payment Fee Percentage	3.33%
Debt Instrument, Basis Spread on Variable Rate	5.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	8.75%

Warrants (Details textual) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 22, 2013 USD ($) $ / shares shares	Sep. 30, 2013 shares	Sep. 30, 2013 USD ($) $ / shares shares	Dec. 31, 2012 shares
Class of Stock [Line Items]
Issuance of Preferred Stock \| $	$ 3,000		$ 30,197
Warrants Exercised Price		200,000
Stock Issued During Period Shares, Warrants Exercised				1,397,937
2013 PIPE investors [Member]
Class of Stock [Line Items]
Number of Investors	17
Purchase of Common stock			12,100
Price per Share \| $ / shares	$ 0.25
Warrants to purchase common shares	6,050,000
Exercise price of Warrants \| $ / shares			$ 0.33
Expiry period for warrants			5 years
Stock Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued In Private Placement Shares	6,400,000
Warrants Issued In Private Placement	3,200,000

Closing of Merger and Financing Transaction (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Common shares outstanding at the date of merger (in thousands)	167,504,447	4,674,495
Cash consideration	$ 293
Total purchase price	$ 94,151
Date of Merger [Member]
Common shares outstanding at the date of merger (in thousands)	61,749
Closing price per share	$ 1.52
Total purchase price	$ 93,858

Closing of Merger and Financing Transaction (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Cash and cash equivalents	$ 597
Accounts receivable	9
Accounts receivable, related party	45
Inventory	50
Other current assets	53
Property and equipment	357
Other long-term asset	2
Intangible assets	10
Goodwill	93,670	$ 0
Total assets acquired	94,793
Accounts payable and other liabilities	642
Total purchase price	$ 94,151

Closing of Merger and Financing Transaction (Details 2) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue	$ 362	$ 531	$ 1,212	$ 1,741
Net loss	$ (11,265)	$ (3,670)	(20,327)	$ (11,694)
Predecessor [Member]
Revenue			25
Net loss			(2,062)
Historical Results of Predecessor Company [Member]
Revenue			1,237
Net loss			$ (22,389)
Historical TransEnterix loss per common share - basic and diluted			$ (0.13)
Pro forma loss per common share - basic and diluted:			$ (0.13)
Pro forma loss			$ (22,389)
Pro forma weighted average common shares			167,502
Pro forma loss per common share			$ (0.13)
Pro Forma Adjustments [Member]
Revenue			$ 0
Net loss			0
Pro Forma Results [Member]
Revenue			1,237
Net loss			(22,389)
SafeStitch Medical, Inc. [Member]
Revenue			1,212
Net loss			$ (20,327)

Closing of Merger and Financing Transaction (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jul. 31, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Debt Instrument [Line Items]
Stock Issued During Period Shares Merger		105,549,746
Stock Issued During Period Value Merger		$ 293,000
Debt Instrument Principal Amount	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Proceeds From Issuance Of Preferred Stock and Preference Stock		28,199,000	$ 268,000
Goodwill		93,670,000		$ 0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets		$ 10,000
Finite-Lived Intangible Assets, Remaining Amortization Period		10 years
Common Stock [Member]
Debt Instrument [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion		10
Private Placement [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues		7,545
Private Placement [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion		10
Series B Redeemable Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Share Price		$ 25,000
Series B Redeemable Convertible Preferred Stock [Member] \| Private Placement [Member]
Debt Instrument [Line Items]
Share Price		$ 4.00

Subsequent Events (Details) - Subsequent Event [Member]	Sep. 30, 2013 USD ($)
Operating Leased Assets [Line Items]
2014	$ 83
2015	114
2016	117
2017	121
2018	124
Operating Leases, Future Minimum Payments Due, Total	$ 559

Subsequent Events (Details Textual) - shares	1 Months Ended
Subsequent Events (Details Textual) - shares	Oct. 31, 2013	Oct. 29, 2013	Sep. 30, 2013	Dec. 31, 2012
Subsequent Event [Line Items]
Common Stock, Shares Authorized			225,000,000	113,000,000
Incentive Compensation Plan 2007 [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			5,000,000
Incentive Compensation Plan 2007 [Member] \| Stock Appreciation Rights (Sars) [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,000,000
Incentive Compensation Plan 2007 [Member] \| Performance Shares [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			500,000
Common Stock [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			10
Private Placement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			10
Subsequent Event [Member]
Subsequent Event [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract	52 months
Lessee Leasing Arrangements, Operating Leases, Renewal Term	6 years
Common Stock, Shares Authorized		750,000,000
Subsequent Event [Member] \| Incentive Compensation Plan 2007 [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	24,700,000
Subsequent Event [Member] \| Incentive Compensation Plan 2007 [Member] \| Stock Appreciation Rights (Sars) [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,500,000
Subsequent Event [Member] \| Incentive Compensation Plan 2007 [Member] \| Performance Shares [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Percentage of Issued and Outstanding Stock Held By Stock Holders	89.00%
Convertible Preferred Stock, Shares Issued upon Conversion	10
Subsequent Event [Member] \| Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Percentage of Issued and Outstanding Stock Held By Stock Holders	98.00%